ELEKTA'S BOARD DECIDES TO REPURCHASE OWN SHARES AND ADJUST NET DEBT/EQUITY OBJECTIVE

ELEKTA'S BOARD DECIDES TO REPURCHASE OWN SHARES AND ADJUST NET DEBT/EQUITY
OBJECTIVE 

PRESS RELEASE	
Stockholm, Sweden, January 23, 2008

The Board of Directors of Elekta AB (publ) has decided to utilize the
authorization the Board received from the Annual General Meeting to repurchase
shares in the company. In conjunction, the Board of Directors has also decided
to adjust the company's financial objective for net debt/equity from below 0.25
to below 0.50. 

Elekta's distribution policy is to distribute 20 percent or more of net profit
to shareholders in the form of dividends, share repurchases or comparable
measures. 

For fiscal years 2004/05 and 2005/06 respectively, dividend together with share
repurchases in the following year, has corresponded to 86 percent and 97 percent
respectively of net profit, in line with the company's ambition to create
shareholder value.

Elekta's Annual General Meeting on September 25, 2007, resolved to authorize the
Board to decide on the acquisition of a maximum of 10 percent of the total
number of shares in the company.

The Board today decided to exercise the mandate by authorizing the executive
management to initiate, on appropriate occasions, the repurchase of shares in an
amount of SEK 100 M, but maximized to 1,200,000 shares.

The total number of shares in Elekta as of December 31, 2007 amounts to
93,903,316 divided between 3,562,500 A shares and 90,340,816 B shares.

Elekta's current holding of shares (treasury stock) amounts to 1,630,871 B
shares, which are in the process of being cancelled according to the decision by
the AGM on September 25. 

A repurchase of 1,200,000 shares is corresponding to 1.3 percent of the total
number of outstanding shares in the company. The Board intends to propose to the
AGM that repurchased shares will be cancelled. 

Purchases will be made on the Nordic Exchange and to a price within the spread
at the time of purchase. Purchases can be made during the time until next Annual
General Meeting.






******

For further information, please contact:

Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 4,500 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.